Edwards Lifesciences Corporation's Stock Analysis

Edwards Lifesciences Announces $500 Million Share Repurchase Agreement

Edwards Lifesciences Corporation has entered into an accelerated share repurchase agreement to buy back $500 million of its common stock. This transaction will add to the more than $800 million in shares the company has repurchased in 2025. The initial delivery will consist of approximately 5 million shares, with the final number determined by the average share price during the agreement's term.

The share repurchase will be funded using the company's existing cash reserves. Following this agreement, Edwards Lifesciences has about $600 million remaining in its share repurchase authorization approved by its Board of Directors. This action may impact the company's stock price as it reflects a commitment to returning value to shareholders.

Aug 19, 2025 16:17:08

Edwards Lifesciences FTC Block Impacts Acquisition Plans and Guidance

Edwards Lifesciences announced that the U.S. Federal Trade Commission has moved to block its proposed acquisition of JenaValve Technology, which the company believes would enhance treatment options for patients with aortic regurgitation. Edwards disagrees with the FTC's decision and plans to continue pursuing regulatory approval, expecting a final determination by the end of the first quarter of 2026.

In light of the FTC's action, Edwards has revised its full-year 2025 financial guidance, maintaining its revenue guidance while increasing its adjusted Earnings Per Share (EPS) guidance to a range of $2.45-$2.55, up from $2.40-$2.50. The company indicated that there would be minimal impact on its third-quarter adjusted EPS guidance.

Aug 06, 2025 13:43:31

Executive Leadership Change at Edwards Lifesciences Announced

Larry L. Wood will resign from his role as Corporate Vice President and Group President, Transcatheter Aortic Valve Replacement and Surgical Structural Heart at Edwards Lifesciences, effective September 1, 2025. He is leaving to take a senior leadership position at another company outside of the cardiovascular sector.

Following Mr. Wood's departure, Daniel J. Lippis, currently the Corporate Vice President for Japan, Greater China, and Asia Pacific, will assume the role of Corporate Vice President responsible for Transcatheter Aortic Valve Replacement starting September 1, 2025.

Jul 24, 2025 18:22:54

Edwards Lifesciences Reports Q2 2025 Financial Results and Guidance

Edwards Lifesciences reported a second quarter sales increase of 11.9% to $1.53 billion, with adjusted sales growth of 10.6%. The Transcatheter Aortic Valve Replacement (TAVR) segment saw an 8.9% growth, contributing $1.1 billion to total sales. The Transcatheter Mitral and Tricuspid Therapies (TMTT) segment experienced significant growth of 61.9%, with sales reaching $134.5 million. The company reported an earnings per share (EPS) of $0.57, with an adjusted EPS of $0.67. Edwards also announced an increase in its sales growth guidance for the year, now expecting a total sales growth of 9-10% and an adjusted EPS range of $2.40 to $2.50 for 2025.

The gross profit margin for the quarter was 77.5%, slightly down from 79.9% the previous year, attributed to higher manufacturing costs and foreign exchange impacts. Selling, general, and administrative expenses rose to $502 million, representing 32.8% of sales. Research and development expenses were $276 million, or 18.0% of sales, reflecting the company's focus on expanding its structural heart portfolio. As of June 30, 2025, cash and cash equivalents totaled approximately $3 billion, with total debt around $600 million. The company anticipates third quarter sales between $1.46 billion and $1.54 billion, with adjusted EPS projected between $0.54 and $0.60.

Jul 24, 2025 16:23:33

Edwards Lifesciences Reports Q1 2025 Financial Results and Guidance

Edwards Lifesciences Corporation announced its financial results for the first quarter of 2025, reporting a 6.2% increase in sales to $1.41 billion. The company’s Transcatheter Aortic Valve Replacement (TAVR) sales grew by 3.8%, while Transcatheter Mitral and Tricuspid Therapies (TMTT) sales saw a significant increase of 58%, reaching $115 million. Earnings per share (EPS) for the quarter were reported at $0.62, with an adjusted EPS of $0.64. The company has received CE Mark approval for the SAPIEN M3 and finalized a National Coverage Determination for transcatheter tricuspid valve replacement, expanding patient access to its EVOQUE product. Additionally, Edwards has raised its TMTT sales guidance for 2025 to a range of $530 million to $550 million and increased its total sales guidance to between $5.7 billion and $6.1 billion due to favorable foreign exchange rates and ongoing business momentum.

The company also reported a gross profit margin of 78.7%, slightly up from 78.4% in the prior year, with operating income at $394.8 million. Selling, general, and administrative expenses were $466 million, representing 33% of sales. Edwards expects some pressure on its operating margin due to the weakening dollar and announced tariffs but maintains its full-year operating margin guidance of 27% to 28%. For the second quarter of 2025, total sales are projected to be between $1.45 billion and $1.53 billion, with an adjusted EPS forecast of $0.59 to $0.65.

Apr 23, 2025 16:33:22

Edwards Lifesciences Reports $1.39 Billion in Q4 Sales

Edwards Lifesciences Corporation reported a 9% increase in fourth quarter sales, reaching $1.39 billion, surpassing expectations. The company experienced notable growth in its Transcatheter Mitral and Tricuspid Therapies (TMTT), with a remarkable 88% increase in sales to $105 million. Additionally, the company presented results from two significant FDA clinical trials which could enhance its product offerings and market position moving forward. The adjusted earnings per share rose to $0.59, reflecting strong overall performance across product lines.

On the downside, the gross profit margin decreased to 78.9%, down from 80.2% in the previous year, indicating a slight decline in profitability. Selling, general, and administrative expenses rose significantly to $492 million, constituting 35.5% of sales, attributed to increased spending on TMTT teams and transition costs after the sale of a segment. Research and development expenses also grew by 12%, totaling $271 million, which may impact future profitability if not managed effectively.

Feb 11, 2025 16:24:18

Edwards Lifesciences Reports Strong Third Quarter Performance

Edwards Lifesciences announced a successful third quarter with a 9% increase in sales from continuing operations, driven mainly by growth in their TAVR and TMTT product lines. The company also reported a significant 73% increase in TMTT sales, alongside a notable one-time gain from the sale of their Critical Care division. Their earnings per share slightly exceeded expectations, and they maintained their sales guidance for the full year, reflecting a positive outlook for the business.

On the downside, the company faced rising operational costs, with selling, general, and administrative expenses increasing by 10% compared to the previous year. Additionally, despite the overall sales growth, the TAVR segment saw only a modest 6% increase, suggesting potential challenges in expanding this market further. While the company's cash position remains strong, concerns about hospital capacity constraints for heart procedures could impact future growth in this area.

Oct 24, 2024 16:28:37

Edwards Lifesciences Announces Major Sale and Share Repurchase

Edwards Lifesciences has completed the sale of its Critical Care product group to BD for $4.2 billion, which will help fund future initiatives and strengthen its focus on structural heart innovations. CEO Bernard Zovighian expressed gratitude for the contributions of the Critical Care team, emphasizing the company's commitment to enhancing patient outcomes through new technologies and therapies.

In addition to the sale, Edwards announced a $1.5 billion share repurchase authorization, which includes a $500 million Accelerated Share Repurchase agreement. Following this, the company has $1.4 billion remaining for future repurchases. This strategic move reflects Edwards' confidence in its growth opportunities, particularly in TAVR and surgical leadership, as it prepares to present its strategy at the upcoming Wells Fargo Healthcare Conference.

Sep 03, 2024 16:34:20

Edwards Lifesciences Reports Strong Q2 Growth Despite TAVR Challenges

Edwards Lifesciences reported a 7% sales growth in Q2 2024, driven by a remarkable 75% increase in TMTT sales. However, TAVR sales growth was lower than expected at 5%. The company lowered its full-year TAVR growth forecast while increasing TMTT guidance. Positive clinical outcomes from the EVOQUE introduction and a pending Critical Care sale add to the optimism, despite slight declines in profit margins.

Jul 24, 2024 16:26:30

Edwards Lifesciences to Acquire Innovalve for Heart Valve Innovation

Edwards Lifesciences is acquiring Innovalve Bio Medical Ltd., an early-stage transcatheter mitral valve replacement company, to enhance their technologies for structural heart patients. The acquisition aims to expand treatment options for mitral disease and support long-term growth. Edwards' SAPIEN M3 system is progressing towards approval in Europe by 2025. The acquisition is set to finalize by the end of 2024, bolstering Edwards' commitment to revolutionizing mitral and tricuspid valve disease treatments.

Jul 15, 2024 09:04:03